Log In
Print
BCIQ
Print
Print this Print this
 

GS-4774 (formerly GI-13020)

  Manage Alerts
Collapse Summary General Information
Company GlobeImmune Inc.
DescriptionWhole heat-killed recombinant Saccharomyces cerevisiae genetically engineered (Tarmogen) to express HBV antigens
Molecular Target HBV antigens
Mechanism of ActionImmunotherapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis B virus (HBV)
Indication DetailsTreat chronic HBV infection
Regulatory Designation

Partner

Gilead Sciences Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today